Sylvester-led study focuses on rate of failure in head and neck cancer trials

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer.

January 23, 2026

Vol.52 No.03

Clinical Roundup

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

Positive results were announced from its two pivotal phase III trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B in over 1,800 patients from 29 countries.

January 16, 2026

Vol.52 No.02

Drugs & Targets

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

The University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has fully implemented the Advarra OnCore Clinical Trials Management System, an investment that strengthens oversight, efficiency, and growth of cancer clinical trials.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

The Alliance for Clinical Trials in Oncology initiated a randomized phase III clinical trial called RECIPROCAL to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

January 09, 2026

Vol.52 No.1

In Brief

Northwell, START unveil $5.7M early-phase clinical trial center

Northwell Health and START Center for Cancer Research have unveiled a $5.7M, 10,000 square foot early-phase cancer clinical trial center that aims to provide better access to treatments for cancer patients in New York and Long Island.

December 19, 2025

Vol.51 No.46

Sylvester-led study focuses on rate of failure in head and neck cancer trials

YOU MAY BE INTERESTED IN

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Bepirovirsen demonstrates positive results in chronic hepatitis B, phase III trials show

UAMS Winthrop P. Rockefeller Cancer Institute expands OnCore to strengthen clinical trials

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

Northwell, START unveil $5.7M early-phase clinical trial center

Renew today!

Subscriber content

Never miss an issue!

Login